BiologicsMD is a preclinical therapeutic company that specializes in developing targeted treatments for hair loss, bone disorders, and oncology through innovative recombinant fusion proteins. These proteins consist of two functional domains: an Active Domain that stimulates specific receptors and a Binding Domain that ensures localized delivery of the treatment to the affected area. This dual-domain approach allows for sustained therapeutic exposure with minimal off-target effects, enabling infrequent dosing—sometimes as rare as once every 1 to 6 months. The company is particularly focused on conditions such as alopecia areata, androgenetic alopecia, and chemotherapy-induced alopecia, where their first-in-class hair cycle stimulators aim to restore hair growth effectively while minimizing side effects compared to existing treatments.

In addition to hair loss treatments, BiologicsMD is also advancing therapies for various bone disorders. Their pipeline includes a new bone graft substitute for spinal fusion, a bone growth stimulator for post-menopausal osteoporosis, and compounds designed to prevent and treat bone metastases in breast and prostate cancer. Similar to their hair loss treatments, these bone disorder therapies utilize the proprietary fusion protein technology, combining an Active Domain for therapeutic response with a Binding Domain that targets and retains the treatment in the bone. This targeted approach aims to provide localized and sustained effects, enhancing the efficacy of treatments for patients suffering from these conditions.

United States

BiologicsMD is developing novel therapeutics and therapeutic-device combinations for the treatment of hair-loss and bone disorders.  The company's portfolio of hair cycle stimulators (HCS) are first-in-class treatments that hold the promise to restore hair and prevent hair loss in conditions of alopecia. The core technology relies on targeting physiologically active agents to Type l collagen found in skin and bone. BiologicsMD's targeted approach minimizes off-target effects and increases the time of exposure at the sites of function.

BiologicsMD

Company Details